IP Verse

Dry Powder Inhaler And Methods Of Use - EP3613421

The patent EP3613421 was granted to Aspeya on May 3, 2023. The application was originally filed on Mar 15, 2013 under application number EP19194560A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3613421

ASPEYA
Application Number
EP19194560A
Filing Date
Mar 15, 2013
Status
Granted And Under Opposition
Mar 31, 2023
Grant Date
May 3, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKFeb 2, 2024ELKINGTON AND FIFEADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONEP1350511
OPPOSITIONUS2002158150
OPPOSITIONWO9737708
SEARCHEP1350511
SEARCHUS2002158150
SEARCHWO9737708

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- HADINOTO et al., "Drug Release Study Of Large Hollow Nanoparticulate Aggregates Carrier Particles For Pulmonary Delivery", International Journal of Pharmaceutics, (20070000), vol. 341, pages 195 - 20
DESCRIPTION- IWAMOTO K., "GASTROINTESTINAL AND HEPATIC FIRST-PASS METABOLISM OF ASPIRIN IN RATS", J Pharm Pharmacol, (19820300), vol. 34, no. 3, pages 176 - 80
DESCRIPTION- DAVID E.GELLER, M. D. et al., "DEVELOPMENT OF AN INHALED DRY-POWDER FORMULATION OF TOBRAMYCIN USING PULMOSPHERETM TECHNOLOGY", J Aerosol Med Pulm Drug Deliv., (20110800), vol. 24, no. 4, doi:doi:10.1089/jamp.2010.0855, pages 175 - 82, XP055121377
OPPOSITION- A. Soleti et al., "Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers", European Respiratory Journal, (2011), vol. 38, XP093148936
OPPOSITION- Bma, "Antiplatelet drugs", British National Formulary 61, BMJ Group and Pharmaceutical Press, (20110101), pages 149 - 152, XP093161535
OPPOSITION- Kevin Taylor, "31. Pulmonary drug delivery", Pharmaceutics: The Science of Dosage Form Design, CHURCHILL LIVINGSTONE, (20020101), pages 473 - 488, XP093161532
OPPOSITION- Michael T. Newhouse, "Informa Healthcare", Encyclopedia of PHARMACEUTICAL TECHNOLOGY Third Edition VOLUME 1 , Informa Healthcare, (20070101), pages 1279 - 1286, XP093161541
OPPOSITION- K. Hadinoto et al., "Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery", International Journal of Pharmaceutics, (2007), vol. 341, doi:10.1016/j.ijpharm.2007.03.035, XP022166304
OPPOSITION- Carlo Patrono, "Low-Dose Aspirin for the Prevention of Atherothrombosis", The New England journal of medicine, Massachusetts Medical Society, US, US , (20051201), vol. 353, no. 22, doi:10.1056/NEJMra052717, ISSN 0028-4793, pages 2373 - 2383, XP093161538
OPPOSITION- Yuxiang Dai, "Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease", Thrombosis, (20121124), vol. 2012, doi:10.1155/2012/245037, ISSN 2090-1488, pages 1 - 7, XP093161529
SEARCH- HADINOTO ET AL, "Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (20070724), vol. 341, no. 1-2, doi:10.1016/J.IJPHARM.2007.03.035, ISSN 0378-5173, pages 195 - 206, XP022166304 [Y] 1-5 * figures 1, 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents